|
| Primary information |
|---|
| ID | 10361 |
| Therapeutic ID | Th1051 |
| Protein Name | Human Serum Albumin |
| Sequence | >Th1051_Human_Serum_Albumin
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
|
| Molecular Weight | 66472.2 |
| Chemical Formula | C2936H4624N786O889S41 |
| Isoelectric Point | 5.67 |
| Hydrophobicity | -0.395 |
| Melting point | 62 |
| Half-life | NA |
| Description | Human serum albumin isolated from expired blood plasma. |
| Indication/Disease | Human Serum Albumin is indicated for treatment of severe blood loss, hypervolemia, hypoproteinemia. |
| Pharmacodynamics | Human Serum Albumin regulates the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentrtion and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation. |
| Mechanism of Action | Human Serum albumin acts as a high molecular weight, very soluble osmolyte. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | NA |
| Categories | Albumins, Amino Acids, Peptides, and Proteins, Blood and Blood Forming Organs, Blood and Related Products, Blood Derivatives, Blood Proteins, Blood Substitutes and Perfusion Solutions, Blood Substitutes and Plasma Protein Fractions, Cardiac Function, Diluents, Human Serum Albumin, Increased Intravascular Volume, Increased Oncotic Pressure, Osmotic Activity, Proteins, Serum Albumin |
| Patents Number | US6723303 |
| Date of Issue | 20-Apr-2004 |
| Date of Expiry | 20-Nov-2025 |
| Drug Interaction | NA |
| Target | Nitric oxide |
| Brand Name | Albuminar |
| Company | CSL Behring |
| Brand Description | CSL Behring |
| Prescribed For | precscribed in treatment of Shock, Burns, Hypoproteinemia with or without edema |
| Chemical Name | NA |
| Formulation | Albumin (Human) 25% (albumin human) is a solution containing in each 100 mL, 25 grams of serum albumin, osmotically equivalent to 500 mL of normal human plasma. The pH of the solution is adjusted with sodium bicarbonate, sodium hydroxide, or acetic acid. Approximate concentrations of significant electrolytes per liter are: sodium - 130-160 mEq; and potassium - n.m.t. 1 mEq. |
| Physical Appearance | Albumin (Human) 25%, is a Sterile aqueous solution of albumin obtained from large pools of adult human venous plasma by low temperature controlled fractionation according to the Cohn process. |
| Route of Administration | Albumin (Human) 25%, Albuminar-25 (albumin human) |
| Recommended Dosage | Albumin (Human) 25%, Albuminar-25 (albumin (human)) may be given intravenously without dilution or it may be diluted with normal saline or 5% dextrose before administration. 200 mL per liter gives a solution which is approximately isotonic and iso-osmotic with citrated plasma. |
| Contraindication | Albumin (Human) 25% may be contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin. |
| Side Effects | Allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. if administered rapidly, may result in vascular overload with resultant pulmonary edema. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |